Cantor Fitzgerald Reaffirms Overweight Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "overweight" rating reaffirmed by Cantor Fitzgerald in a note issued to investors on Friday,Benzinga reports. They presently have a $170.00 target price on the biotechnology company's stock. Cantor Fitzgerald's price objective suggests a potential upside of 34.38% from the stock's current price.

Other equities analysts have also issued research reports about the stock. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 17th. Citigroup upped their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. JPMorgan Chase & Co. decreased their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating on the stock in a research report on Wednesday, October 23rd. Jefferies Financial Group boosted their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a research note on Tuesday, August 13th. Finally, Wells Fargo & Company raised their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $191.77.

Ascendis Pharma A/S Stock Up 1.8 %

Shares of NASDAQ:ASND traded up $2.23 during trading on Friday, reaching $126.51. 1,448,850 shares of the company traded hands, compared to its average volume of 450,130. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00. The firm has a market cap of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66. The firm has a fifty day simple moving average of $132.30 and a 200 day simple moving average of $132.70.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. As a group, research analysts anticipate that Ascendis Pharma A/S will post -7.35 EPS for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Groupama Asset Managment bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $60,000. Signaturefd LLC increased its position in shares of Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock worth $102,000 after purchasing an additional 80 shares during the last quarter. Bessemer Group Inc. raised its stake in shares of Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company's stock worth $132,000 after purchasing an additional 332 shares in the last quarter. Searle & CO. acquired a new stake in shares of Ascendis Pharma A/S in the 2nd quarter valued at approximately $205,000. Finally, Rhumbline Advisers grew its stake in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after buying an additional 143 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.